Wallace L. Akerley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wallace L. Akerley has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Jhanelle Elaine Gray
Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
26 shared publications - Jonathan W. Riess
Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, CA 95817, USA
26 shared publications - Asma Taj
Michigan CRC NCORP/St. Mary's of Michigan, Saginaw, Michigan
25 shared publications - David R. Gandara
University of California Davis Comprehensive Cancer Center, Sacramento, CA
25 shared publications - Gregory J. Gerstner
Heartland NCORP/Illinois Cancer Care-Peoria, Peoria, Illinois
25 shared publications - James Moon
Fred Hutchinson Cancer Center 20
25 shared publications
Latest Publications
- Open Access
- 28 March 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (4) , 380
Real-world management and outcomes of immune-mediated diarrhea and colitis: gaps in guideline adherence and opportunities for implementation
Purpose Immune-mediated diarrhea and colitis (IMDC) is a high-risk toxicity frequently experienced by patients treated with immune checkpoint inhibitors (ICIs) and requiring rapid supportive care interventions. Delays in IMDC reporting and inconsistent guideline adherence increase symptom burden and emergency department (ED) utilization. Although current practice guidelines provide IMDC management recommendations, adherence in routine oncology care remains uncertain. This study evaluated management and guideline concordance for clinically significant IMDC at a single National Cancer Institute–designated comprehensive cancer center to identify workflow opportunities to improve supportive management. Methods We conducted a retrospective observational study of adults treated with ICIs between 2011 and 2024 who developed IMDC requiring systemic immunosuppression. Electronic health record (EHR) data were used to characterize patient demographics, IMDC reporting patterns, and to assess National Comprehensive Cancer Network (NCCN) guideline concordance in terms of IMDC diagnostic workup and management across care settings. Results ED clinicians demonstrated greater adherence to NCCN guidelines than outpatient oncology providers. Of the 17 patients with IMDC, nine (52.94%) required ED management, with an average immunosuppressive therapy duration of 92.29 days, and only four (23.53%) resumed ICI therapy following IMDC resolution. Despite 88.24% of patients presenting with moderate-severe IMDC, 41.18% experienced symptoms for over a week before seeking medical care. Over 40% of patients with IMDC experienced concurrent immune-related adverse events (irAEs), with dermatitis and hepatitis being the most common. Conclusion Our findings reveal actionable targets for improving supportive management of clinically significant IMDC. Implementing standardized workflows and decision-support tools may strengthen evidence-based IMDC care, reduce treatment delays, and improve patient outcomes.
- 28 March 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (4) , 380
Open AccessReal-world management and outcomes of immune-mediated diarrhea and colitis: gaps in guideline adherence and opportunities for implementation
Purpose Immune-mediated diarrhea and colitis (IMDC) is a high-risk toxicity frequently experienced by patients treated with immune checkpoint inhibitors (ICIs) and requiring rapid supportive care interventions. Delays in IMDC reporting and inconsistent guideline adherence increase symptom burden and emergency department (ED) utilization. Although current practice guidelines provide IMDC management recommendations, adherence in routine oncology care remains uncertain. This study evaluated management and guideline concordance for clinically significant IMDC at a single National Cancer Institute–designated comprehensive cancer center to identify workflow opportunities to improve supportive management. Methods We conducted a retrospective observational study of adults treated with ICIs between 2011 and 2024 who developed IMDC requiring systemic immunosuppression. Electronic health record (EHR) data were used to characterize patient demographics, IMDC reporting patterns, and to assess National Comprehensive Cancer Network (NCCN) guideline concordance in terms of IMDC diagnostic workup and management across care settings. Results ED clinicians demonstrated greater adherence to NCCN guidelines than outpatient oncology providers. Of the 17 patients with IMDC, nine (52.94%) required ED management, with an average immunosuppressive therapy duration of 92.29 days, and only four (23.53%) resumed ICI therapy following IMDC resolution. Despite 88.24% of patients presenting with moderate-severe IMDC, 41.18% experienced symptoms for over a week before seeking medical care. Over 40% of patients with IMDC experienced concurrent immune-related adverse events (irAEs), with dermatitis and hepatitis being the most common. Conclusion Our findings reveal actionable targets for improving supportive management of clinically significant IMDC. Implementing standardized workflows and decision-support tools may strengthen evidence-based IMDC care, reduce treatment delays, and improve patient outcomes.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Table 3. Patient Characteristics for those with and without assay results
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Table 3. Patient Characteristics for those with and without assay results
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Table 2. Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Table 2. Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Figure 1. Progression-Free Survival and Overall Survival in patients with cancers with TP53 co-mutations, and STK11 co-mutations.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Figure 1. Progression-Free Survival and Overall Survival in patients with cancers with TP53 co-mutations, and STK11 co-mutations.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Table 1. Dose Modifications for Docetaxel and Trametinib
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Supplementary Table 1. Dose Modifications for Docetaxel and Trametinib
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Figure 1. Progression-Free Survival and Overall Survival in patients with cancers with TP53 co-mutations, and STK11 co-mutations.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Figure 1. Progression-Free Survival and Overall Survival in patients with cancers with TP53 co-mutations, and STK11 co-mutations.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Figure 1. Progression-Free Survival and Overall Survival in patients with cancers with TP53 co-mutations, and STK11 co-mutations.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Figure 1. Progression-Free Survival and Overall Survival in patients with cancers with TP53 co-mutations, and STK11 co-mutations.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Table 2. Representativeness of Study Participants
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Table 2. Representativeness of Study Participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Table 2. Representativeness of Study Participants
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Table 2. Representativeness of Study Participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Table 3. Patient Characteristics for those with and without assay results
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
Supplementary Table 3. Patient Characteristics for those with and without assay results